Axogen, Inc. (AXGN): Price and Financial Metrics

Axogen, Inc. (AXGN)

Today's Latest Price: $14.37 USD

0.09 (-0.62%)

Updated Nov 23 6:55pm

Add AXGN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

AXGN Stock Summary

  • AXGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 216.67 -- higher than 85.99% of US-listed equities with positive expected earnings growth.
  • Axogen Inc's stock had its IPO on March 27, 1990, making it an older stock than 84.52% of US equities in our set.
  • With a year-over-year growth in debt of 1,376.61%, Axogen Inc's debt growth rate surpasses 98.52% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Axogen Inc, a group of peers worth examining would be SNES, SPNE, PWFL, ISR, and OXFD.
  • AXGN's SEC filings can be seen here. And to visit Axogen Inc's official web site, go to

AXGN Stock Price Chart Interactive Chart >

Price chart for AXGN

AXGN Price/Volume Stats

Current price $14.37 52-week high $18.84
Prev. close $14.46 52-week low $7.16
Day low $14.27 Volume 131,400
Day high $14.66 Avg. volume 412,437
50-day MA $13.14 Dividend yield N/A
200-day MA $11.14 Market Cap 576.61M

Axogen, Inc. (AXGN) Company Bio

AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company is based in Alachua, Florida.

AXGN Latest News Stream

Event/Time News Detail
Loading, please wait...

AXGN Latest Social Stream

Loading social stream, please wait...

View Full AXGN Social Stream

Latest AXGN News From Around the Web

Below are the latest news stories about Axogen Inc that investors may wish to consider to help them evaluate AXGN as an investment opportunity.

AxoGen Struggling Through A Protracted Restructuring

Small-cap med-tech AxoGen (AXGN) already had plenty of long-running challenges to deal with before the pandemic, and the decline in elective pressures has only added to the challenges and pressures. While AxoGen’s core product offers what I believe to be meaningful advantages over autografts and synthetic conduits, the company’s sales...

Stephen Simpson, CFA on Seeking Alpha | October 2, 2020

Global Nerve Repair and Regeneration Market Outlook 2020: Company Profiles of Key Players Axogen, Baxter, Nevro, Nuvectra, Polyganics and Stryker -

DUBLIN--(BUSINESS WIRE)--The "Nerve Repair and Regeneration - Global Market Outlook (2018-2027)" report has been added to's offering. The Global Nerve Repair and Regeneration market accounted for $6.46 billion in 2018 and is expected to reach $21.68 billion by 2027 growing at a CAGR of 14.4% during the forecast period. Some of the key factors propelling the market growth are technological developments for nerve repair and regeneration and an increase in healthcare expense

Business Wire | August 10, 2020

AxoGen's (AXGN) CEO Karen Zaderej on Q2 2020 Results - Earnings Call Transcript

AxoGen, Inc. (AXGN) Q2 2020 Earnings Conference Call August 05, 2020 4:30 PM ET Company Participants Pete Mariani – Chief Financial Officer Karen Zaderej – Chairman, Chief Executive Officer and President Conference Call Participants Raj Denhoy – Jefferies Dan Stauder – JMP Securities Jamie Morgan – SVB Leerink Brandon Folkes...

SA Transcripts on Seeking Alpha | August 6, 2020

Axogen RECON Clinical Study Completes Target Enrollment of 220 Subjects

RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve GraftALACHUA, Fla., July 22, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that its phase 3 pivotal RECONSM Clinical Study supporting its Biologics License Application (BLA) submission for Avance Nerve Graft has reached its enrollment target of 220 subjects. RECON compares Avance Nerve Graft to manufactured conduits in digital nerve injuries with a primary endpoint of return of sensation and secondary endpoints for quality of life and patient satisfaction. “We are pleased to have reached this important milestone and appreciate the dedicatio...

Yahoo | July 22, 2020

Axogen, Inc. to Report Second Quarter 2020 Financial Results and Host Conference Call on August 5, 2020

ALACHUA, Fla., July 15, 2020 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral.

Yahoo | July 15, 2020

Read More 'AXGN' Stories Here

AXGN Price Returns

1-mo 6.13%
3-mo 29.87%
6-mo 56.54%
1-year -15.42%
3-year -44.84%
5-year 162.71%
YTD -19.68%
2019 -12.43%
2018 -27.81%
2017 214.44%
2016 80.00%
2015 39.28%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8042 seconds.